170 related articles for article (PubMed ID: 25551245)
1. Attitudinal barriers to prescribing LAI antipsychotics in the outpatient setting: communicating with patients, families, and caregivers.
Kane JM
J Clin Psychiatry; 2014 Dec; 75(12):e33. PubMed ID: 25551245
[TBL] [Abstract][Full Text] [Related]
2. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
Kane JM; McEvoy JP; Correll CU; Llorca PM
CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
[TBL] [Abstract][Full Text] [Related]
3. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives.
Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
Can J Psychiatry; 2013 May; 58(5 Suppl 1):23S-9S. PubMed ID: 23945064
[TBL] [Abstract][Full Text] [Related]
4. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
[TBL] [Abstract][Full Text] [Related]
5. Patient outcomes within schizophrenia treatment: a look at the role of long-acting injectable antipsychotics.
Bera RB
J Clin Psychiatry; 2014; 75 Suppl 2():30-3. PubMed ID: 24919169
[TBL] [Abstract][Full Text] [Related]
6. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
7. Monitoring treatment and managing adherence in schizophrenia.
Marder SR
J Clin Psychiatry; 2013 Oct; 74(10):e21. PubMed ID: 24229761
[TBL] [Abstract][Full Text] [Related]
8. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
9. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
Potkin S; Bera R; Zubek D; Lau G
BMC Psychiatry; 2013 Oct; 13():261. PubMed ID: 24131801
[TBL] [Abstract][Full Text] [Related]
10. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence.
Correll CU
J Clin Psychiatry; 2014 Nov; 75(11):e29. PubMed ID: 25470105
[TBL] [Abstract][Full Text] [Related]
11. [Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].
Azorin JM
Encephale; 2013 Sep; 39 Suppl 2():S121-3. PubMed ID: 24084422
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.
Aggarwal NK; Sernyak MJ; Rosenheck RA
J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006
[TBL] [Abstract][Full Text] [Related]
13. Rethinking the role of long-acting atypical antipsychotics in the community setting.
Altamura AC; Aguglia E; Bassi M; Bogetto F; Cappellari L; De Giorgi S; Fagiolini A; Ferrannini L; Girardi P
Int Clin Psychopharmacol; 2012 Nov; 27(6):336-49. PubMed ID: 22859065
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia.
Kane JM; Correll CU
J Clin Psychiatry; 2019 Sep; 80(5):. PubMed ID: 31536686
[TBL] [Abstract][Full Text] [Related]
15. Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
Correll CU; Lauriello J
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505193
[TBL] [Abstract][Full Text] [Related]
16. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
[TBL] [Abstract][Full Text] [Related]
17. Clinical guideline recommendations for antipsychotic long-acting injections.
Kane JM; Garcia-Ribera C
Br J Psychiatry Suppl; 2009 Nov; 52():S63-7. PubMed ID: 19880920
[TBL] [Abstract][Full Text] [Related]
18. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years.
Patel MX; Haddad PM; Chaudhry IB; McLoughlin S; Husain N; David AS
J Psychopharmacol; 2010 Oct; 24(10):1473-82. PubMed ID: 19477883
[TBL] [Abstract][Full Text] [Related]
19. Historical perspective on antipsychotic long-acting injections.
Johnson DA
Br J Psychiatry Suppl; 2009 Nov; 52():S7-12. PubMed ID: 19880921
[TBL] [Abstract][Full Text] [Related]
20. Barriers to utilizing long-acting injectable antipsychotic medications.
Getzen H; Beasley M; D'Mello DA
Ann Clin Psychiatry; 2013 Nov; 25(4):E1-6. PubMed ID: 24199223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
